<DOC>
	<DOCNO>NCT00480532</DOCNO>
	<brief_summary>The purpose study learn study drug , doxycycline , decrease amount unplanned vaginal bleeding woman commonly experience take combine oral contraception ( COC ) - pill estrogen progestin - continuous fashion - hormone-free week . The study drug , doxycycline , antibiotic use commonly many condition ( i.e . acne , Chlamydia infection , pneumonia ) safely use daily basis . Doxycycline show decrease unplanned vaginal bleed progestin-only contraception study combined hormonal contraception .</brief_summary>
	<brief_title>A Study Continuous Oral Contraceptives Doxycycline</brief_title>
	<detailed_description>We intend conduct prospective , randomize , placebo control , double blind study Oregon Health Science University . This study conduct four 28-day cycle ( 112 day active COC hormone ) . All woman enrol study take daily low dose COC . This protocol divide two study , bleed study endometrial biopsy study , two treatment arm ; typical dose doxycycline ( Arm 1 ) , control release subantimicrobial dose doxycycline ( CRSD ) ( Arm 2 ) . The first arm ( Arm 1 ) study constitute typical dose doxycycline arm . In arm , two study group . Group 1 , treatment group , take doxycycline 100 mg orally twice day five day start first day bleed breakthrough bleeding occurs . The control group take placebo orally twice day five day start first day bleed breakthrough bleeding occurs . After three month , group stop doxycycline ( placebo ) continue COC alone remain 28 day study . The second arm ( Arm 2 ) study constitute control release subantimicrobial dose doxycycline ( CRSD doxycycline ) arm . Subjects arm study divide Group 3 Group 4 . Group 3 take CRSD doxycycline ( 40mg ) daily three month . Group 4 take daily placebo . Similarly first arm trial , three month , group stop doxycycline ( placebo ) continue COC alone remain 28 day study . This study also include endometrial biopsy sub-study : At time recruitment identify participant willing undergo endometrial biopsy study period . These subject constitute separate cohort enroll prospective , randomize , double blind , placebo control endometrial biopsy study .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<mesh_term>Ethinyl estradiol , levonorgestrel drug combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>General good health Willing able agree randomization sign inform consent Currently regular menstrual cycle ( 2436 day ) , combine cyclic hormonal method ( COCs , Nuva Ring , Ortho Evra ) , without intermenstrual bleeding last 2 year . Intrauterine device ( IUD ) place Abnormal pap smear treat follow Those hypersensitivity reaction doxycycline tetracycline Use depomedroxyprogesterone acetate within 9 month start study . Use hormonal medication ( exclude cyclic contraceptive plan B ) within 2 month start study . Any one unwilling keep daily menstrual diary otherwise unwilling follow study criterion Currently take medication interfere COCs ( rifampin , carbamazepine , St. Johns wort ) Currently progestin implant Positive Gonorrhea Chlamydia culture enrollment examination Smoking 5 cigarette per month Any medical condition contraindication use COCs accordance product label include : History thrombophlebitis , deep venous thrombosis , thrombogenic vasculopathies , thrombogenic rhythm disorder thromboembolic disorder Current past history cerebrovascular coronary artery disease Scheduled major surgery next six month prolong immobilization Diabetes vascular involvement Headache focal neurologic symptom Uncontrolled hypertension Suspected know carcinoma breast personal history breast cancer Carcinoma endometrium know suspected estrogen dependent neoplasm Undiagnosed genital bleed History cholestatic jaundice pregnancy cholestatic jaundice prior oral contraceptive use Hepatic adenoma carcinoma active liver disease liver function return normal Known suspect pregnancy Hypersensitivity estrogen progesterone containing product</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>birth control</keyword>
	<keyword>continuous contraception</keyword>
	<keyword>break-through bleeding</keyword>
</DOC>